Business
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH),
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nFourth quarter revenue growth of 39% driven by strong Oncology and Screening volume\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025.\n\n\nFourth quarter 2025 preliminary unaudited financial results\n\n\nFor the three-month period ended December 31, 2025, as compared to the same period of 2024:\n\n\n\nTotal revenue of approximately $280 million, an increase of 39%\n\n\n\nReported approximately 79,000 oncology tests, an increase of 38%\n\n\n\nReported approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period\n\n\n\nFull year 2025 preliminary unaudited financial results\n\n\nFor the twelve-month period ended December 31, 2025, as compared to the same period of 2024:\n\n\n\nTotal revenue of approximately $981 million, an increase of 33%\n\n\n\nReported approximately 276,000 oncology tests, an increase of 34%\n\n\n\nReported approximately 87,000 Shield screening tests\n\n\n\n“2025 was a breakout year for Guardant, with total revenue growth accelerating to 33% year-over-year,” said Helmy Eltoukhy, co-founder and co-CEO. “We saw exceptional volume growth in Oncology over the last year, primarily driven by pioneering innovation from our Smart Platform and best-in-class commercial execution. We expect this momentum to continue throughout the year with the launch of multiple groundbreaking products that will fuel the next phase of growth in our Oncology business.”\n\n\n“We are incredibly proud of Shield's strong momentum as we continue to strengthen our leadership in the blood-based colorectal cancer screening market, with Shield positioned as one of the most successful diagnostic launches to date,” said AmirAli Talasaz, co-founder and co-CEO. “Since FDA approval, nearly 100,000 patients have been screened with Shield. We have now expanded Shield to include multi-cancer detection findings, further enhancing the clinical value of the platform for both patients and physicians. Together, these milestones will further advance the fight against cancer in 2026 and beyond.”\n\n\nPreliminary unaudited free cash flow was approximately negative $54 million for the fourth quarter of 2025, and approximately negative $233 million for the full yea...